INTRODUCTION {#s1}
============

Tuberculosis (TB) is a chronic infectious disease caused by *Mycobacterium tuberculosis* (MTB). Data from the global tuberculosis report estimated a worldwide incidence of 8.7 million cases, most of which occurred in Asia and Africa \[[@R1]\]. One-third of the world\'s population is potentially infected with *M. tuberculosis*, but only 10% of the infected individuals eventually develop clinical TB, indicating that the host\'s genetic and other factors (such as alcohol consumption, malnutrition, and human immunodeficiency virus infection) may play essential and complex roles in determining susceptibility and progression to tuberculosis \[[@R2]--[@R4]\]. An increasing number of studies have focused on the relationship between genetic variations of several genes and TB susceptibility \[[@R5], [@R6]\].

Currently, the gene encoding interferon-γ (*IFNG*) is the most extensively studied gene regarding tuberculosis susceptibility. Human *IFNG* is located on chromosome 12 (12q14) and has four exons spanning approximately 6 kb. Interferon-γ (IFN-γ), which is encoded by *IFNG* and produced by T helper 1 (Th1) lymphocytes, is upregulated and secreted as a major cytokine to activate macrophages, and is critical for the control of *M. tuberculosis* infection \[[@R7]\]. Cases of active TB are characterized by decreased production of IFN-γ from the peripheral blood mononuclear cells compared with that observed in latent infection. In addition, local and systemic IFN-γ levels correlate with the severity of the disease \[[@R8]\].

Lio et al. first noted a significant association between the +874A/T polymorphism (rs2430561) in *IFNG* and protection against TB in Sicilia (*P* \< 0.05) \[[@R9]\]. The SNP +874 (A/T) is located at the 5′-end of a CA repeat in the first intron of the human *IFNG* \[[@R10]\]. The +874 T-allele is linked to the 12 CA repeats, whereas the A-allele is linked to the non-twelve CA repeats \[[@R11]\]. The specific sequence of the T-allele provides a binding site for the transcription factor nuclear factor-κB \[[@R12], [@R13]\]. As nuclear factor-κB induces IFN-γ expression, the presence of the T-allele correlates with high IFN-γ expression, whereas that of the A-allele correlates with low expression.

Many epidemiologic studies, including meta-analyses \[[@R14], [@R15]\], suggested associations between *IFNG* *+874 T/A* (rs2430561) polymorphism and the risk of developing TB. However, the data were inconsistent, partly because of differences in study populations and case ascertainment criteria, or small sample sizes with a high rate of false-positives and limited power of detecting modest associations. Considering the important role of *IFNG* *+874 T/A* (rs2430561) polymorphism in TB development, we studied all eligible case-control studies that included characteristics such as ethnicity of the patients, types of tuberculosis, and control sources.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

Using various combinations of key terms, 152 article titles were retrieved by a literature search using the PubMed and SinoMed databases. As shown in Figure [1](#F1){ref-type="fig"}, 66 articles were excluded after screening the abstracts of the manuscripts. The full texts were evaluated, and 47 additional articles were excluded because of the following reasons: duplication (two), meta-analysis (seven), review (twelve), discussion on polymorphism in other diseases (tegumentary leishmaniasis and leprosy) (two), other SNPs in *IFNG* (one), IFNG receptor gene polymorphisms (fifteen), and other genes (three), and lacked case-control study (five). Finally, 39 different articles \[[@R9], [@R16]--[@R53]\] concerning *IFNG* *+874 T/A* (rs2430561) polymorphism and TB susceptibility were included in our meta-analysis (Table [1](#T1){ref-type="table"}). Overall, 42 case-control studies with 8,574 cases and 9,011 controls were retrieved based on the search criteria. The controls were mainly healthy populations. First, we checked the Minor Allele Frequency (MAF) reported for the five main worldwide populations in the 1000 Genomes Browser: East Asian, 0.8413; European, 0.5378; African, 0.8327; American, 0.7464; and South Asian, 0.6104. The MAF in our analysis was 0.324 and 0.382 in the case and control group, respectively, both lower than the results in the 1000 Genomes Browser database. Then, the frequency of the T-allele was found to be significantly higher in case individuals of Caucasian ethnicity than in those of African or mixed ethnicities (41.3% vs. 22.9%, *P* = 0.005, or 41.3% vs. 27.2%, *P* = 0.017, respectively). A similar trend was found in the control group (Figure [2](#F2){ref-type="fig"}). Except for seven studies \[[@R16], [@R21], [@R26], [@R30], [@R36], [@R38], [@R43]\], the distribution of genotypes in all the controls was in agreement with Hardy-Weinberg equilibrium (HWE).

![Flowchart illustrating the search strategy used to identify association studies for *IFNG +874 T/A* (rs2430561) polymorphism and tuberculosis risk](oncotarget-08-50415-g001){#F1}

###### Basic information for included studies of the association between *IFNG +874 T/A (rs2430561*) polymorphism site and tuberculosis susceptibility

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author            Year   Origin         Source of Control   Ethnicity   Type          Sample size   Case   Control   Case                                 Control   Control                 Methods   NOS          
  ----------------------- ------ -------------- ------------------- ----------- ------------- ------------- ------ --------- ------ ----- ----- ------- --------- --------- --------- ----- ------- --------- ------------ ---
  Amim\*\[[@R34]\]        2008   Brazil         HB                  Mixed       TB            \<100         93     266       15     25    53    0.296   0.0006    67        88        111   0.417   0.001     PCR-ARMS     6

  Anand\[[@R21]\]         2010   India          HB                  Asian       PTB           \<100         62     66        7      27    28    0.331   0.898     8         25        33    0.311   0.35      PCR-ASP      6

  Ansari\*\[[@R53]\]      2009   Pakistan       HB                  Asian       PTB           \>100         111    188       27     47    37    0.455   0.123     25        87        76    0.364   0.98      PCR-ARMS     7

  Ansari\*\[[@R53]\]      2009   Pakistan       HB                  Asian       EPTB          \<100         77     188       12     36    29    0.389   0.881     25        87        76    0.364   0.98      PCR-ARMS     7

  Anuradha\*\[[@R27]\]    2008   India          PB                  Asian       Children TB   \<100         25     90        5      13    7     0.46    0.815     29        42        19    0.555   0.6       PCR          6

  Asgharzadeh\[[@R64]\]   2016   Iran           PB                  Asian       TB            \>100         124    200       10     42    72    0.25    0.281     28        81        91    0.342   0.15      PCR-ARMS     8

  Bhanothu\[[@R47]\]      2015   India          HB                  Asian       EPTB          \>100         175    100       45     87    43    0.506   0.941     29        62        9     0.6     0.003     ARMS-MG/\    6
                                                                                                                                                                                                              MP-PCR       

  Cooke\*\[[@R36]\]       2006   UK             PB                  African     PTB           \>100         667    597       20     159   488   0.149   0.115     13        166       415   0.162   0.45      PCR-ARMS     6

  Ding\*\[[@R26]\]        2008   China          PB                  Asian       TB            \>100         301    310       19     89    193   0.211   0.052     32        114       164   0.287   0.07      sequencing   8

  Etokebe\*\[[@R40]\]     2005   Croatia        HB                  Caucasian   TB            \>100         242    519       53     122   67    0.471   0.637     103       282       134   0.47    0.04      PCR-ASP      6

  Fitness\*\[[@R48]\]     2004   Malawi         PB                  African     TB            \>100         451    703       12     134   305   0.175   0.549     17        219       467   0.179   0.14      PCR-ARMS     8

  Gutlapalli\[[@R32]\]    2016   India          HB                  Asian       TB            \>100         247    129       73     123   51    0.544   0.951     60        58        11    0.689   0.56      PCR-ARMS     6

  Hashemi\[[@R20]\]       2011   Iran           PB                  Asian       PTB           \>100         142    166       18     84    40    0.422   0.011     33        111       22    0.533   0.001     PCR-ARMS     7

  Hu\[[@R45]\]            2015   China          PB                  Asian       TB            \>100         360    480       36     124   200   0.272   0.013     67        201       212   0.349   0.08      PCR-ARMS     7

  Hwang\*\[[@R50]\]       2007   Korea          PB                  Asian       PTB           \<100         80     80        1      13    66    0.094   0.696     0         21        59    0.131   0.17      PCR-ARMS     7

  Leandro\[[@R43]\]       2013   Brazil         PB                  Mixed       TB            \>100         172    179       22     78    72    0.354   0.902     26        91        62    0.399   0.42      PCR-ARMS     8

  Lee\[[@R44]\]           2015   Taiwan         PB                  Asian       TB            \>100         200    202       131    56    13    0.795   0.046     144       54        4     0.846   0.68      TaqMan       8

  Lio\[[@R9]\]            2002   Italy          PB                  Caucasian   PTB           \<100         45     97        4      30    11    0.422   0.013     25        47        25    0.5     0.06      PCR-ARMS     8

  Lopez-\                 2003   Spain          PB                  Caucasian   PTB           \>100         113    100       11     40    62    0.274   0.238     19        50        31    0.44    0.88      PCR          6
  Maderuelo\*\[[@R39]\]                                                                                                                                                                                                    

  Ma\*\[[@R49]\]          2007   China          PB                  Asian       PTB           \<100         60     60        2      10    48    0.117   0.138     8         20        32    0.3     0.11      PCR-SSP      6

  Mabunda\[[@R29]\]       2015   Brazil         HB                  Mixed       PTB           \>100         101    360       3      32    66    0.188   0.708     21        136       203   0.247   0.77      TaqMan       7

  Moran\*\[[@R30]\]       2007   USA            PB                  African     TB            \>100         240    174       9      87    144   0.219   0.348     11        65        98    0.25    0.96      sequencing   7

  Moran\*\[[@R30]\]       2007   USA            PB                  Caucasian   TB            \<100         161    64        24     92    45    0.435   0.039     16        31        17    0.492   0.8       sequencing   7

  Moran\*\[[@R30]\]       2007   USA            PB                  Caucasian   TB            \<100         319    98        24     96    199   0.226   0.013     10        26        62    0.235   0.01      sequencing   7

  Mosaad\[[@R42]\]        2010   Egypt          HB                  Caucasian   TB            \>100         110    118       32     60    18    0.563   0.253     52        60        6     0.695   0.03      PCR-ARMS     6

  Onay\*\[[@R22]\]        2010   Turkey         HB                  Caucasian   Children TB   \<100         40     67        9      22    9     0.5     0.527     16        35        16    0.5     0.71      PCR-ARMS     6

  Oral\*\[[@R35]\]        2006   Turkey         PB                  Caucasian   TB            \<100         81     50        21     29    31    0.438   0.014     8         21        21    0.37    0.48      PCR-SSP      8

  Rossouw\*\[[@R38]\]     2003   UK             PB                  African     TB            \>100         313    235       25     102   186   0.243   0.078     26        98        111   0.319   0.53      PCR          6

  Sallakci\*\[[@R33]\]    2007   Turkey         HB                  Caucasian   TB            \>100         361    115       50     182   129   0.391   0.262     26        58        31    0.478   0.91      sequencing   6

  Selma\*\[[@R25]\]       2011   Tunisia        PB                  African     TB            \>100         223    150       38     85    100   0.361   0.009     22        86        42    0.433   0.04      PCR-RFLP     7

  Selvaraj\*\[[@R52]\]    2008   India          HB                  Asian       PTB           \>100         160    178       20     72    68    0.35    0.889     23        76        79    0.342   0.48      PCR-RFLP     7

  Shen\[[@R28]\]          2013   China          PB                  Asian       Children TB   \>100         189    164       136    53    0     0.859   0.024     133       29        2     0.899   0.77      sequencing   6

  Tso\*\[[@R37]\]         2005   Hong Kong      HB                  Asian       TB            \>100         385    451       17     101   267   0.175   0.068     55        190       206   0.332   0.28      sequencing   6

  Vallinoto\*\[[@R23]\]   2010   Brazil         PB                  Mixed       TB            \>100         162    156       11     58    93    0.247   0.635     24        86        46    0.429   0.12      PCR-ASO      7

  Vidyarani\*\[[@R31]\]   2006   India          HB                  Asian       PTB           \>100         129    127       14     54    61    0.318   0.694     20        52        55    0.362   0.2       PCR-ARMS     6

  Wang\*\[[@R54]\]        2011   China          HB                  Asian       PTB           \>100         273    297       3      78    192   0.154   0.107     3         84        210   0.151   0.08      PCR-RFLP     6

  Wang\*\[[@R24]\]        2010   China          PB                  Asian       PTB           \>100         521    526       14     80    427   0.104   \<0.001   10        91        425   0.105   0.06      PCR-RFLP     6

  Wit\*\[[@R51]\]         2011   South Africa   PB                  Mixed       TB            \>100         500    315       40     194   266   0.274   0.579     33        124       158   0.301   0.24      PCR-RFLP     6

  Wu\*\[[@R41]\]          2008   China          PB                  Asian       PTB           \<100         61     122       1      10    50    0.098   0.554     2         24        96    0.114   0.72      PCR-RFLP     8

  Yang\*\[[@R57]\]        2010   China          HB                  Asian       PTB           \>100         189    191       6      41    142   0.14    0.168     3         49        139   0.143   0.57      PCR-SSP      6

  Zhong\[[@R55]\]         2014   China          HB                  Asian       PTB           \>100         142    166       4      26    112   0.119   0.117     7         49        110   0.189   0.61      TaqMan       6

  Zhuang\[[@R56]\]        2009   China          HB                  Asian       PTB           \>100         167    167       12     53    102   0.231   0.172     37        70        60    0.431   0.06      PCR-SSP      5
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HWE: Hardy--Weinberg equilibrium; HB: hospital-based; PB: population-based; TB: tuberculosis; PTB: pulmonary TB, EPTB: extra-pulmonary TB; PCR-FLIP: polymerase chain reaction and restrictive fragment length polymorphism; PCR-ARMS: polymerase chain reaction-amplification refractory mutation specific; PCR-ASP: allele specific primers by polymerase chain reaction, PCR-SSP: polymerase chain reaction-sequence specific primer; PCR-ASO: polymerase chain reaction-allele-specific oligonucleotide; ARMS-MG/MP-PCR: Amplification refractory mutation system-multi gene/multi primer polymerase chain reaction; NOS: Newcastle-Ottawa Scale; \*: studies reported in previous meta-analysis; bold: these nine studies including both PTB and EPTB.

![T-allele frequencies for the *IFNG +874 T/A* (rs2430561) polymorphism among cases/controls stratified by ethnicity\
Vertical line, T-allele frequency; Horizontal line, ethnicity type.](oncotarget-08-50415-g002){#F2}

Quantitative synthesis {#s2_2}
----------------------

In the overall analysis, a significant protective association could be observed between TB risk and the variant genotype of *IFNG* *+874 T/A* (rs2430561) polymorphism in different genetic models. For example, for the additive model (TA vs. AA), odds ratios (OR) = 0.71, 95% confidence intervals (CI) = 0.63-0.80, *P-*value of heterogeneity test (*P*~h~) = 1×10^-6^, and in the dominant model, OR = 0.68, 95% CI = 0.60-0.77, *P*~h~ = 1×10^-6^ (Figure [3](#F3){ref-type="fig"}, Table [2](#T2){ref-type="table"}). If some studies that do not conform to HWE were removed, these associations were not affected.

![Forest plot of tuberculosis risk associated with *IFNG +874 T/A* (rs2430561) polymorphism (additive model, TA vs. AA) in the whole\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](oncotarget-08-50415-g003){#F3}

###### Total and stratified subgroup analysis for *IFNG +874 T/A(rs2430561*) polymorphism site and tuberculosis susceptibility

  Variables           N    Case/       Allelic effect                          Additive model (TA vs. AA)/(TT vs. AA)                                     Dominant model                          Recessive model                      Overdominant model
  ------------------- ---- ----------- ------------------------------------ -- ----------------------------------------------------------------------- -- ------------------------------------ -- --------------------------------- -- ------------------------------------
  Total               42   8574/9011   0.75 (0.68-0.82) 1×10^-6^ 1×10^-6^      0.71 (0.63-0.80) 1×10^-6^ 1×10^-6^/0.60 (0.49-0.73) 1×10^-6^ 1×10^-6^      0.68 (0.60-0.77) 1×10^-6^ 1×10^-6^      0.72 (0.62-0.83) 0.002 1×10^-6^      0.83 (0.76-0.92) 1×10^-6^ 1×10^-6^
  HWE                 35   7270/7594   0.75 (0.67-0.84) 1×10^-6^ 1×10^-6^      0.74 (0.65-0.83) 1×10^-6^ 1×10^-6^/0.62 (0.49-0.78) 1×10^-6^ 1×10^-6^      0.71 (0.62-0.81) 1×10^-6^ 1×10^-6^      0.70 (0.59-0.83) 0.004 1×10^-6^      0.85 (0.76-0.94) 0.001 0.002
  Ethnicity                                                                                                                                                                                                                            
  Asian               23   4180/4648   0.73 (0.63-0.84) 1×10^-6^ 1×10^-6^      0.68 (0.57-0.81) 1×10^-6^ 1×10^-6^/0.58 (0.42-0.81) 1×10^-6^ 0.001         0.65 (0.54-0.79) 1×10^-6^1×10^-6^       0.70 (0.57-0.87) 0.004 0.001         0.83 (0.72-0.95) 0.005 0.006
  Caucasian           9    142/1228    0.79 (0.65-0.97) 0.013 0.025            0.83 (0.63-1.09) 0.095 0.181/0.60 (0.39-0.92) 0.014 0.019                  0.77 (0.58-1.03) 0.036 0.078            0.70 (0.49-0.96) 0.003 0.028         0.99 (0.84-1.17) 0.135 0.926
  African             5    1894/1859   0.84 (0.75-0.95) 0.276 0.004            0.74 (0.57-0.94) 0.026 0.016/0.79 (0.58-1.09) 0.276 0.152                  0.75 (0.60-0.94) 0.048 0.013            0.97 (0.72-1.30) 0.392 0.833         0.76 (0.61-0.95) 0.047 0.017
  Mixed               5    1028/1276   0.67 (0.52-0.84) 0.009 0.003            0.64 (0.45-0.92) 0.012 0.015/0.53 (0.42-0.72) 0.009 1×10^-6^               0.61 (0.42-0.87) 0.004 0.007            0.64 (0.48-0.85) 0.545 0.002         0.75 (0.57-0.97) 0.094 0.030
  Source of Control                                                                                                                                                                                                                    
  HB                  18   3064/3693   0.76 (0.64-0.91) 1×10^-6^ 0.003         0.72 (0.59-0.87) 1×10^-6^ 0.001/0.59 (0.41-0.86) 1×10^-6^ 0.006            0.69 (0.54-0.86) 1×10^-6^ 0.001         0.72 (0.55-0.94) 1×10^-6^ 0.016      0.85 (0.73-0.98) 0.030 0.023
  PB                  24   5510/5318   0.74 (0.68-0.82) 0.003 1×10^-6^         0.70 (0.61-0.81) 0.001 1×10^-6^/0.60 (0.49-0.75) 0.030 1×10^-6^            0.68 (0.59-0.79) 1×10^-6^ 1×10^-6^      0.71 (0.63-0.82) 0.246 1×10^-6^      0.82 (0.72-0.94) 0.001 0.004
  TB type                                                                                                                                                                                                                              
  PTB                 25   4244/5107   0.73 (0.64-0.83) 1×10^-6^ 1×10^-6^      0.68 (0.58-0.80) 0.001 1×10^-6^/0.60 (0.44-0.81) 1×10^-6^ 0.001            0.66 (0.55-0.78) 1×10^-6^ 1×10^-6^      0.71 (0.57-0.90) 0.006 0.004         0.80 (0.70-0.91) 0.008 0.001
  EPTB                10   984/1910    0.66 (0.55-0.79) 0.040 1×10^-6^         0.55 (0.39-0.77) 0.027 1×10^-6^/0.45 (0.27-0.75) 0.007 0.002               0.51 (0.36-0.73) 0.008 1×10^-6^         0.66 (0.49-0.89) 0.075 0.006         0.88 (0.66-1.17) 0.007 0.347
  Sample size                                                                                                                                                                                                                          
  \<100               12   1104/1248   0.82 (0.67-0.99) 0.043 0.047            0.89 (0.72-1.09) 0.323 0.262/0.70 (0.53-0.94) 0.283 0.018                  0.83 (0.69-1.01) 0.161 0.056            0.71 (0.54-0.92) 0.253 0.011         0.82 (0.67-0.99) 0.043 0.047
  \>100               30   7470/7763   0.73 (0.66-0.81) 1×10^-6^ 1×10^-6^      0.67 (0.59-0.76) 0.000 0.000/0.56 (0.45-0.72) 0.000 0.000                  0.64 (0.56-0.74) 1×10^-6^ 1×10^-6^      0.71 (0.61-0.84) 0.001 1×10^-6^      0.81 (0.73-0.89) 0.001 1×10^-6^
  Genotype methods                                                                                                                                                                                                                     
  PCR-SSP             4    497/468     0.64 (0.33-1.22) 1×10^-6^ 0.177         0.60 (0.45-0.80) 0.109 0.001/0.58 (0.14-2.30) 1×10^-6^ 0.437               0.57 (0.31-1.08) 0.002 0.088            0.69 (0.21-2.33) 0.002 0.558         0.68 (0.51-0.90) 0.555 0.007
  PCR                 3    451/425     0.62 (0.50-0.77) 0.346 1×10^-6^         0.57 (0.42-0.77) 0.356 1×10^-6^/0.46 (0.29-0.72) 0.439 0.001               0.54 (0.41-0.72) 0.291 1×10^-6^         0.59 (0.38-0.90) 0.689 0.015         0.68 (0.51-0.90) 0.390 0.007
  sequencing          7    1956/1376   0.69 (0.55-0.86) 0.003 0.001            0.78 (0.55-1.11) 0.001 0.173/0.45 (0.34-0.59) 0.153 1×10^-6^               0.71 (0.50-1.00) 0.001 0.050            0.52 (0.41-0.66) 0.729 1×10^-6^      0.97 (0.69-1.37) 1×10^-6^ 0.858
  PCR-ARMS            15   2845/3545   0.78 (0.68-0.90) 0.001 0.001            0.77 (0.69-0.86) 0.105 1×10^-6^/0.65 (0.46-0.92) 1×10^-6^ 0.014            0.73 (0.61-0.87) 0.005 0.001            0.76 (0.59-0.98) 0.012 0.034         0.87 (0.79-0.97) 0.350 0.014
  PCR-RFLP            6    1738/1588   0.91 (0.80-1.03) 0.640 0.131            0.84 (0.65-1.08) 0.042 0.177/0.87 (0.64-1.18) 0.793 0.360                  0.87 (0.75-1.01) 0.114 0.072            0.98 (0.73-1.31) 0.771 0.902         0.85 (0.67-1.09) 0.045 0.204
  TaqMan              3    443/728     0.67 (0.53-0.84) 0.771 0.001            0.59 (0.42-0.83) 0.377 0.002/0.39 (0.19-0.79) 0.714 0.009                  0.57 (0.41-0.79) 0.357 0.001            0.72 (0.49-1.05) 0.795 0.084         0.79 (0.60-1.04) 0.149 0.095
  PCR-ASP             2    284/585     1.02 (0.83-1.24) 0.761 0.871            0.93 (0.67-1.29) 0.359 0.675/1.03 (0.68-1.55) 0.997 0.891                  0.96 (0.71-1.31) 0.464 0.809            1.11 (0.78-1.58) 0.725 0.570         0.91 (0.69-1.20) 0.318 0.505

*P*~h~: value of *Q*-test for heterogeneity test; *P*: *Z*-test for the statistical significance of the OR. HWE: Except for seven studies\[[@R20],[@R25],[@R30],[@R34],[@R40],[@R42],[@R47]\], the distribution of genotypes in the controls in remaining 35 studies was in agreement with HWE, and it reports the meta-analysis results of studies showing no deviation from the HWE.

In the ethnicity type subgroup, this pattern of positive association was maintained in the whole genetic models. For example, for the allelic effect, OR = 0.84, 95% CI = 0.75-0.95, *P*~h~ = 0.276 for Africans; OR = 0.73, 95% CI = 0.63-0.84, *P*~h~ = 1×10^-6^ for Asians; OR = 0.79, 95% CI = 0.65-0.97, *P*~h~ = 0.013 for Caucasians; OR = 0.67, 95% CI = 0.52-0.84, *P*~h~ = 0.009 for mixed ethnicity (Figure [4](#F4){ref-type="fig"}, Table [2](#T2){ref-type="table"}). Similar results were detected in the source of control analysis. For example, in the dominant model, OR = 0.69, 95% CI = 0.54-0.86, *P*~h~ = 1×10^-6^ for HB, and OR = 0.68, 95% CI = 0.59-0.79, *P*~h~ = 1×10^-6^ for PB (Figure [5](#F5){ref-type="fig"}, Table [2](#T2){ref-type="table"}).

![Forest plot of tuberculosis risk associated with *IFNG +874 T/A* (rs2430561) polymorphism (the allelic effect) by ethnicity\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](oncotarget-08-50415-g004){#F4}

![Forest plot of tuberculosis risk associated with *IFNG +874 T/A* (rs2430561) polymorphism (dominant model) by source of control\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](oncotarget-08-50415-g005){#F5}

In the stratified analysis by TB type, significant associations were found with both pulmonary tuberculosis (PTB) and extra-pulmonary tuberculosis (EPTB) risks and *IFNG* *+874 T/A* (rs2430561) polymorphism in the five genetic models. For example, for the additive model (TT vs. AA), OR = 0.60, 95% CI = 0.44-0.81, *P*~h~ = 1×10^-6^ for PTB, and OR = 0.45, 95% CI = 0.27-0.75, *P*~h~ = 0.007 for EPTB (Figure [6](#F6){ref-type="fig"}, Table [2](#T2){ref-type="table"}).

![Forest plot of tuberculosis risk associated with *IFNG +874 T/A* (rs2430561) polymorphism (additive model, TT vs. AA) by type of tuberculosis\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](oncotarget-08-50415-g006){#F6}

To improve our study, finally we made stratified subgroup analyses according to genotyping methods and sample size. Some positive associations were also found in this section (Table [2](#T2){ref-type="table"}).

Bias diagnosis and sensitivity analysis {#s2_3}
---------------------------------------

The Begg\'s funnel plot and Egger\'s test were performed to access the publication bias of the literature. The shape of the funnel plot did not reveal any obvious asymmetry, and the Egger\'s test suggested the absence of publication bias. For example, in the additive model (TA vs. AA) analysis, z = 1.11, *P* = 0.269 for Begg\'s test and t = −0.87, *P* = 0.389 for Egger\'s test (Figures [7](#F7){ref-type="fig"}, [8](#F8){ref-type="fig"}, Table [3](#T3){ref-type="table"}). We used a sensitivity analysis to determine whether modification of the meta-analysis inclusion criteria affected the results. No single study qualitatively influenced the summary ORs, as indicated by the sensitivity analysis (for example, the allelic effect, Figure [9](#F9){ref-type="fig"}).

![Begg\'s funnel plot for publication bias test (additive model, TA vs. AA)\
Each point represents a separate study for the indicated association. Log \[OR\], natural logarithm of OR. Horizontal line, mean effect size.](oncotarget-08-50415-g007){#F7}

![Egger\'s publication bias plot (additive model, TA vs. AA)](oncotarget-08-50415-g008){#F8}

###### Publication bias tests (Begg\'s funnel plot and Egger\'s test for publication bias test) for *IFNG +874 T/A(rs2430561*) polymorphism

  Egger\'s test                                                                     Begg\'s test   
  ------------------------------ -------- ------- ------- ------- ----------------- -------------- -------
  Allelic effect                 -0.521   0.946   -0.55   0.585   (-2.432,1.390)    0.26           0.795
  Additive model (TA *vs*. AA)   -0.443   0.509   -0.87   0.389   (-1.473, 0.587)   1.11           0.269
  Additive model (TT *vs*. AA)   -0.08    0.345   -0.23   0.817   (-0.778, 0.617)   0.09           0.931
  Dominant model                 -0.414   0.545   -0.76   0.452   (-1.516, 0.688)   1              0.319
  Recessive model                -0.108   0.381   0.28    0.779   (-0.663, 0.878)   0.76           0.448
  Overdominant model             -0.559   0.687   -0.81   0.42    (-1.945, 0.829)   0.89           0.347

![Sensitivity analysis between IFNG +874 T/A (rs2430561) polymorphism and tuberculosis risk (the allelic effect)](oncotarget-08-50415-g009){#F9}

DISCUSSION {#s3}
==========

To understand the pathogenesis of TB and better predict individual risk, it is important to identify the SNPs that affect the function of genes contributing to TB susceptibility. Genome-wide association studies (GWAS) allow genotyping of frequent genetic polymorphisms in the genome without assuming the genomic location of the causal variants. As most of the genome has been surveyed, GWAS eliminates the disadvantages associated with the single polymorphism or candidate gene approach where only a few polymorphisms are investigated \[[@R54]\]. However, GWAS may identify false associations, and therefore, replication or validation of the results in independent populations is essential \[[@R55]\]. A Wellcome Trust Case-Control Consortium-based study initiated GWAS that considered up to 2,000 cases and controls each for tuberculosis and malaria. This study identified *NRAMP1*, *IFNG*, *NOS2A*, *MBL*, *VDR*, and certain TLR-associated genes as important for susceptibility to TB and malaria, and the list has been growing ever since \[[@R55]--[@R57]\].

Lio et al. \[[@R9]\] were the first to investigate the association between *IFNG* *+874 T/A* (rs2430561) polymorphism and the risk of developing TB. Since then, other researchers have reproduced their work on *IFNG* in different populations and for two disparate types of TB. However, the results were confounding, even within populations. Meta-analysis provides a means for effectively increasing the size of the sample by pooling data from individual correlation studies, thus enhancing the statistical power of the analysis to estimate genetic effects \[[@R58]\]. We used this method to demonstrate statistically significant genetic associations.

To the best of our knowledge, this is the first systematic meta-analysis exploring the associations between *IFNG* polymorphism and TB risk. Our analysis involved about 8,574 individuals with TB and 9,011 controls. The main discovery of our study was that the T-allele of the *IFNG* *+874 T/A* (rs2430561) polymorphism showed a protective effect for TB susceptibility, which was consistent with the observation that the presence of the T-allele correlates with high IFN-γ expression and increased resistance to *M. tuberculosis* infection, whereas the A-allele correlates with low expression. The highlight of our article is that we classified TB into PTB and EPTB, which assisted in the analysis of effective target sites for different types of TB, and thereby, we provided a novel concept compared to the previously published meta-analyses \[[@R14], [@R15]\].

Although considerable efforts and resources have been invested in examining the possible associations between IFN gene polymorphisms and TB risk, certain inherent limitations exist. First, although we collected all eligible studies, the sample sizes of these studies were not large enough to provide adequate statistical power to evaluate the association between this polymorphism and TB risk, particularly for certain ethnicities. Thus, not only was there an increased likelihood of type I/II error, but also a lack of sufficient statistical power to evaluate the association between these polymorphisms and tuberculosis risk. Second, because of the complex nature of the immune system and the polygenic nature of complex diseases, such as TB, it has become increasingly evident that gene-gene interactions play a far more important part in an individual\'s susceptibility to tuberculosis than single polymorphisms would on their own \[[@R59]\]. Specific environmental and lifestyle factors, including age, sex, smoking habits, familial history, and disease stage, may possibly alter the associations between *IFNG* polymorphisms and TB. Therefore, it is necessary to evaluate the roles of specific environmental factors and lifestyles in disease prognosis.

In spite of these drawbacks, our meta-analysis provided several advantages. First, a substantial number of cases and controls were pooled from different studies, which significantly increased the statistical power of the analysis. Second, no publication bias was found and the Newcastle-Ottawa Scale (NOS) scores of the included studies indicated high quality. Third, our study contained the highest number of individuals so far, which conferred increased statistical power and credibility. The power of this meta-analysis of *+874 T/A* (rs2430561) polymorphism was greater than 0.95, which suggested that the data was trustworthy.

In conclusion, our present meta-analysis suggests that the *+874 T/A* (rs2430561) polymorphism in *IFNG* may be associated with the risk of developing TB. Further studies that consider additional gene-environment interactions and are based on larger sample sizes should be conducted to elucidate the role of *IFNG* polymorphisms in the etiology and clinical characteristics of TB development.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We searched the PubMed and SinoMed (<http://www.sinomed.ac.cn/>) databases through October 2016, using the keywords "tuberculosis," "TB," "polymorphism," and "IFN-gamma." One hundred and fifty-two articles were retrieved, 39 of which satisfied our inclusion criteria. We also screened references of the retrieved articles and reviewed all articles via a manual search.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

For inclusion, studies were required to (i) assess the association between TB risk and *IFNG* *+874 T/A* (rs2430561) polymorphism; (ii) be case-controlled, and (iii) contain all three kinds of genotypes (TT, TA, and AA) for cases and controls. Studies were excluded if they (i) included no control population; (ii) did not report genotype frequency data, and (iii) were duplicated publications.

Quality score assessment {#s4_3}
------------------------

The NOS \[[@R60]\] was selected to assess the quality of each study. This measure assesses aspects of the methodologies used in observational studies, which are related to the study quality, including selection of cases, comparability of populations, and ascertainment of exposure to risks. The NOS rating ranges from zero stars (worst) to nine stars (best). Studies with a score of seven stars or greater were considered to be of high quality.

Data extraction {#s4_4}
---------------

Two authors independently extracted the data that complied with the selection criteria. These data included the first author\'s last name, year of publication, country of origin, ethnicity of the study population, TB type, genotypes of both the case and control groups, source of control, HWE/ MAF in both case and control groups, and genotyping method. Ethnicity was categorized as Caucasian, Asian, African, and mixed population. The control subgroups were population-based (PB) and hospital-based (HB). The TB type included PTB and EPTB. All included studies were classified as larger (both number of case and control ≥ 100 samples) and medium-sized studies. The NOS score was also shown in this section.

Statistical analysis {#s4_5}
--------------------

Based on the genotype frequencies for cases and controls, OR with 95% CI were used to measure the strength of the associations between the *+874 T/A* (rs2430561) single nucleotide polymorphism (SNP) in *IFNG* and TB risk. The statistical significance of the OR was determined with the *Z*-test. The heterogeneity assumption among studies was evaluated using a χ^2^-based *Q*-test. A *P*-value of \> 0.10 for the *Q-*test indicated a lack of heterogeneity among studies. If significant heterogeneity was detected, the DerSimonian-Laird random-effects model was used; otherwise, the Mantel-Haenszel fixed-effects model was chosen \[[@R61], [@R62]\]. We investigated the relationship between *IFNG* *+874 T/A* (rs2430561) polymorphism and tuberculosis risk by testing the allelic effect (T vs. A), additive model (TT vs. AA and TA vs. AA), dominant model (T carriers vs. AA), recessive model (TT vs. A carriers), and overdominant model (TA vs. AA + TT). A sensitivity analysis was performed by successively omitting studies to assess the stability of the results. The departure of frequencies of the *IFNG* *+874 T/A* (rs2430561) polymorphism from the expected under HWE was assessed by Pearson\'s χ^2^ test, and *P* \< 0.05 was considered significant \[[@R63]\]. Publication bias was assessed by both Egger\'s test and Begg\'s test, and a *P*-value \< 0.05 was considered significant \[[@R64]\]. All statistical tests for this meta-analysis were performed using the Stata software version 11.0 (StataCorp LP, College Station, TX, USA). The power of our meta-analysis was calculated online using the website <http://www.power-analysis.com/>.

Genotyping methods {#s4_6}
------------------

Genotyping of the *IFNG* *+874 T/A* (rs2430561) SNP was conducted using methods described in the retrieved literature, such as polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), polymerase chain reaction-amplification refractory mutation specific (PCR-ARMS), polymerase chain reaction-allele specific primers (PCR-ASP), polymerase chain reaction-sequence specific primer (PCR-SSP), polymerase chain reaction-allele-specific oligonucleotide (PCR-ASO), and amplification refractory mutation system-multi gene/multi primer polymerase chain reaction (ARMS-MG/MP-PCR).
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TB

:   tuberculosis

PB

:   population-based

HB

:   hospital-based

MTB

:   Mycobacterium tuberculosis

IFNG

:   interferon-γ

Th1

:   T helper 1

PTB

:   pulmonary tuberculosis

EPTB

:   extra-pulmonary tuberculosis

HWE

:   Hardy-Weinberg equilibrium

MAF
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:   Genome-wide association studies
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:   polymerase chain reaction-restriction fragment length polymorphism

PCR-ARMS

:   polymerase chain reaction-amplification refractory mutation specific

PCR-ASP

:   polymerase chain reaction-allele specific primers

PCR-SSP

:   polymerase chain reaction-sequence specific primer

PCR-ASO

:   polymerase chain reaction-allele-specific oligonucleotide

ARMS-MG/MP-PCR

:   amplification refractory mutation system-multi gene/multi primer polymerase chain reaction
